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Background: HIV-infected long-term non-progressor (LTNP) subjects can prevent viral replication and may harbor
useful information for the development of both antibody and active vaccination treatments. In this study we used
LTNP sera to examine the epitopes presented to the gp160 protein, and from this procedure we hope to elucidate
potential biomarkers pertaining to the level of resistance a patient may have in developing AIDS after infection with
HIV. We used five clinical sera samples from LTNP patients to identify common epitopes by ELISA; peptides with
high binding to sera were selected and analyzed for conservation among HIV clades. Antibodies were generated
against one identified epitope using a chimeric peptide in BALB/c mice, and both the sera from these mice and
LTNP sera were tested for viral inhibition capabilities.
Results: A monoclonal antibody, CL3, against one identified epitope was used to compare these epitopes
neutralizing capability. LTNP sera was also studied to determine chemokine/cytokine changes in these patients. The
sera from LTNP patients 2, 3, 4, and 5 were identified as having the highest titers, and also significantly inhibited
syncytia formation in vitro. Finally, the protein cytokine array demonstrated that I-309 and IGFBP-1 decreased in
LTNPs, but levels of TIMP-1 and NAP-2 increased significantly.
Conclusions: Our results indicate that the use of LTNP samples may be a useful for identifying further anti-viral
epitopes, and may be a possible predictor for determining if patients show higher resistances of converting the
HIV infection to AIDS.
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Cell-mediated immunity (CMI) is important in the control
of the immune system and its downstream effects, and
plays a vital role in the elimination of viral infections [1].
In infections pertaining to the human immunodeficiency
virus (HIV), the humoral response has also been shown to
play a distinct role in preventing and containing infections
[2]. As branches of the immune system, both cellular and
humoral, play a critical role in the management of HIV
and viral infections, it is important that potential vaccina-
tions or treatments mimic these effects.
In the past, passive antibody therapy has served as a strat-
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unless otherwise stated.[3-7]. In vivo studies have demonstrated the ability of
passive immunotherapy to neutralize HIV or SHIV
(Simian-human immunodeficiency virus) in animal models
[8-14]. Thus, intensive efforts have been made to generate
and characterize novel, efficacious neutralizing anti-HIV
human antibodies [15,16]. Only a few anti-HIV-1 human
monoclonal antibodies (HuMAbs) have been shown to
neutralize clinical HIV-1 isolates from HIV infected human
B cells. These include b12 and F105, which are directed
against the CD4-binding domain of gp120 [17-19], 2G12,
which binds to a conserved epitope on the gp120 envelope
protein [20,21], and 2F5 & 4E10, which are directed to a
highly conserved region of the transmembrane gp41
outside the immunodominant region [22-24].
Several groups have demonstrated that use of a single
antibody is not likely to have a clinically significant
prophylactic or therapeutic effect against HIV-1 [25-28].
As such, multi-component antibody therapies (e.g.
“cocktails”) have been proposed as a more effectiveis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tiple neutralization epitopes. Development of novel anti-
HIV antibodies with broad neutralizing activities may
have considerable prophylactic and therapeutic potential
as component parts of a “cocktail” preparation. One such
HuMAb combination, consisting of 2F5 and 2G12, was
tested in a phase I clinical trial and showed a significant
decrease in viral loads in several participants [29,30].
With the success of HAART (highly active antiretro-
viral therapy), HIV-infected subjects can now live for de-
cades longer than what was previously thought.
However, at this point there is still no known “cure-all”
vaccine that can prevent and treat HIV infection. There
is likewise no known antibodies can completely stop
viral replication in HIV-infected subjects. For many
years, scientists have tried to identify novel epitopes
within the HIV peptides, and to develop some combin-
ation of an antibody cocktail relating to many diverse
epitopes of HIV to help prevent HIV replication.
In recent years, there have, unfortunately, been few
breakthroughs towards further development of antibody
therapy and vaccine development against HIV/AIDS. In
order to design a novel method for the identification of
conserved HIV epitopes, we recruited 5 HIV-infected
long-term non-progressor (LTNP) subjects. LTNP sub-
jects are patients infected with HIV but have some cap-
abilities of controlling the virus without anti-retroviral
therapy. LTNP patients harbor a great deal of useful in-
formation for the development of vaccines/antibody
treatments, as these patients naturally control infections.
In one study, published in 2006, substantially higher
levels of 2G12-like antibodies were found in LTNP pa-
tients than in the control group, suggesting a higher
humoral response in these patients when looking at the
HIV-1 envelope epitope [31]. Herein, we report the de-
velopment and use of an epitope mapping method using
LTNP sera for future novel antibody identification, and
this method is carried out on the gp160 protein product
of the HIV envelope gene (env). Through this procedure,
we were able to identify and documents previously dis-
covered epitope, as well as novel epitopes in this region.
The lab also studied the neutralization of a clinical viral
isolate of HIV-1 by the CL3 antibody, generated in a
HIV-1 infected long-term non-progressor (LTNP) sub-
ject. CL3 is a monoclonal antibody (designated clone 3)
which was found in a previous research study to recog-
nized 10 amino acids (GCSGKLICTT) within the immu-
nodominant region (cluster I) of the transmembrane
envelope glycoprotein gp41, and was able to neutralize
viral infection to target cells [32]. Besides epitope identi-
fication, we also used a protein array assay to find novel
protein changes (chemokine, cytokine, etc.) in LTNP
subjects when compared to the control. We believe such
methods could be the most effective and most beneficialapproach in finding novel epitope and anti-viral factors.
Those factors identified from LTNPs can be used to gen-
erate a treatment cocktail, or add antiviral antibodies to
existing drug cocktails. This may also be used as an
evaluation tool regarding the level of resistance a par-
ticular patient might have as to the timeline regarding
the progress of AIDS development.
Methods
Ethics Statement
Long term HIV-1 infected LTNPs with elevated anti-
HIV antibody titers were used as blood plasma and cell
donors. All LTNP subjects had been infected with HIV-1
clade B for over 15 years without progression to AIDS.
The University of South Florida’s (USF) Institutional Re-
view Board (IRB) on human research, in accordance with
the ethical principles set forth by the World Medical As-
sociation (WMA) and the Declaration of Helsinki, and
USF’s Institutional Animal Care and Use Committee
(IACUC) approved all protocols and methods associated
with this study, and all patients studied in the manu-
script gave written informed consent for participation in
the study.
Blood collection
Long term HIV-1 infected LTNPs with elevated anti-
HIV antibody titers were used as blood plasma and cell
donors. All LTNP subjects had been infected with HIV-1
clade B for over 15 years without progression to AIDS.
Antibody binding analysis (epitope mapping)
HIV-1 MN gp160 peptides (obtained from the AIDS Re-
search and Reference Reagent Program) containing over-
lapping amino acids were used for ELISA assays as
follows. 96 well plates (Immulon II, Dynatech) were
coated with different overlapping gp41 peptides and in-
cubated for 60 min at 37°C. The LTNP patient sera were
diluted in serial dilutions and incubated for 60 min at
37°C. After washing, a mouse anti human immuno-
globulin (IgG or IgM) conjugated to horseradish perox-
idase (HRP) was added. HIV-1 negative (normal human
sera) controls were used in all plates. Following incuba-
tion and washing, TMB substrate was added to the wells
as described above. Following color development, the re-
action was quantified at 450 nm. Wells with a reading at
least three times higher than the background reading in
the last two dilutions (i.e. the two diluted sample) were
considered positive for binding.
Identification of the consensus sequence of each epitope
by “blast” function
Each of the peptide sequences was copied and put into
the sequence editor module of DNAStar. A search for
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ology percentage among amino acids was obtained.
Analysis of CL3 Epitope Homology
HIV gp41 amino acid sequences were analyzed from the
GenBank databank, and available gp41 sequences were
analyzed with “MegAlign” using DNAStar software. The
amino acid sequence GCSGKLIC was used as a stand-
ard, and each “MegAlign” sequence was compared to
this. Identical or different amino acids were recorded at
each residue, followed by sequence comparison analysis.
Results were represented as percent homology.
Peptide vaccine design and vaccination
A chimeric peptide with three CL3 epitopes linked by
GKGKGK was synthesized and mixed with an MPL ad-
juvant. The resulting mixture was injected into three dif-
ferent BALB/c mice. Blood was collected 10 days after
injection. The antibody titer was measured with an
ELISA assay using HIV gp41 recombinant proteins.
Syncytia forming inhibition assay
Sera from LTNP patients and mice injected with the
above chimeric peptide was diluted at different serial di-
lutions and mixed with H9MN. After a 30-minute incu-
bation period, they were added to MT2 cells. After a
24 hours incubation period, the number of syncytia was
determined using light microscopy.
Antibodies used in neutralization profiles
CL3 was purified using Protein A agarose beads (Invitro-
gen, CA). 2F5 and 2G12 were generated and purified by
Polymun (Vienna, Austria). Human IgG (designated
Cont IgG, purchased from Sigma Chemical Co (St.
Louis, MO) was used as a negative control. An add-
itional non-HIV-1 neutralizing HuMAb, designated
ContHuMAb (control HuMAb), was also tested as a
control reagent.
Neutralization of Clinical Isolates
The virus stock of HIV-1 was expanded in phytohem-
agglutinin (PHA) -stimulated peripheral blood mono-
nuclear cells (PBMCs). For all experiments, viruses were
passaged in vitro only once from the original virus
stocks to maintain previously established phenotypes.
PBMCs used for all neutralization assays were either iso-
lated from HIV-uninfected donors by Ficoll-Hypaque
centrifugation, or from (for assays performed at the Uni-
versity of South Florida) Leukopaks, whole blood of indi-
vidual donors purchased from Florida Blood Services
(St. Petersburg. FL).
Neutralization assays utilized a virus from the panel of
clinical clade B HIV-1 isolates upon recommendation by
the National Institutes of Health (NIH), Division ofAIDS, and others [18]. These assays were performed
with modifications according to the protocol of Zolla-
Pazner and Sharpe [33].
Briefly, antibodies were tested starting at 50 μg/mL
(50 μl/ well) in triplicates, with subsequent analysis of
four-fold dilutions. Fifty microliters of virus at 1000
TCID50/ml were added to each well. The mixture was
incubated for 1 hour at 37°C in a CO2 (5%) incubator.
After incubation, 106 PHA-stimulated and polybrene-
treated PBMCs in 100 (l assay medium containing 20%
fetal bovine serum (FBS) were added to each antibody/
virus mixture and incubated for 2.5 hours at 37°C. After
washing twice, the cells were suspended in culture media
containing 10 U/ml IL-2, and incubated at 37°C for 6–9
days. Samples were then lysed by the addition of 20 (l
10% Triton X-100 in phosphate-buffered saline (PBS)
per well and incubated at 37°C for 1 hour. HIV-1 p24
concentrations in each well were measured as described.
Cytokine and Chemokine Array of LTNP Samples
In order to determine which cell-mediated factors played
a role in LTNP survival, a cytokine array of T-cells from
LTNP patients was conducted. The protein assay was con-
ducted using RayBio Assay Human Cytokine Array,
strictly following the manufacturer’s protocol. In short,
array membranes were blocked in blocking buffer at room
temperature for 30 minutes. After washing, samples of
serum from patients (1:10 diluted) were incubated with a
membrane at room temperature for 1 to 2 hours. After
another wash, the membrane was incubated with a pri-
mary biotin-Ab, followed by washing and exposure to
HRP-streptavidin as the secondary antibody. The mem-
brane was subsequently washed and developed with ECL
substrate followed by a chemiluminescence imaging sys-
tem. The results were quantified using volume array ana-
lysis in Gel analysis software.
Statistical Analysis
For the ELISA and vaccine portions, data are expressed
as the mean ± SD and analyzed using a one-way analysis
of variance (ANOVA), and post hoc analysis between
groups was analyzed with Fisher’s LSD test. The level of
statistical significance was deemed to be P < 0.05.
Results
LTNP sera shows high antibody binding to recombinant
HIV-1 gp 160 protein
Sera from five LTNP subjects (LTNP-1, LTNP-2, LTNP-
3, LTNP-4, and LTNP-5) and normal serum (NMS) were
tested against the entire peptide library of HIV-1 MN
Env gp160 protein using an ELISA assay. All subjects
showed antibody binding to the gp41 portion of the
gp160 protein, and sera from LTNP-2 and LTNP-3 had
the highest antibody end point titers (Figure 1).
Figure 1 LTNP Sera Analysis. Sera from five LTNP subjects (LTNP-1, LTNP-2, LTNP-3, etc.) and normal serum (NMS) were tested against HIV-1 gp160
protein using an ELISA assay. All 5 subjects had been infected with HIV-1 clade B for over 15 years without developing into AIDS. All subjects showed
considerable antibody binding at the endpoint titer, with subjects LTNP-2 and LTNP-5 (patient 25) having the highest antibody end point titers.
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After testing the sera against the whole peptide library
of HIV-1 MN Env protein, we successfully mapped pep-
tides with high binding to those sera. Seven epitopes
were successfully mapped. The sequences and the hom-
ology results of a blast search are listed here: Epitope A:
QARLLLSGIVQQQMNLLRAT, 100% identical for 100
out of 100 sequences; Epitope B: GCSGKLICTTTVPW-
NASWSNKSL, range from 95.7-100%, 20 out of 100 are
100%, and 75 out of 100 are 95.7%, however the core
epitope KLIC is 100% identical; Epitope C: LLELDK-
WASLWNWFDITNWLW, 100%, 100 out of 100 se-
quences, Epitope D: DITNWLWYIKI 100%, 100 out of
100 sequences; Epitope E: WYIKIFIMIVGGLVGLRIVF,
range from 90-100%, 3 out of 100 are 90%, 82 out of 100
are 95%, and 15 out of 100 are 100%); Epitope F:
PEGIEEEGGERDRDTRGRLV, range from 85-100%, 8 se-
quences are 85%, and 92 out of 100 are 100%, and Epi-
tope G: IWVDLRSLFLFSYH, range from 92.9-100%, 2
out of 100 are 92.9 and the rest of them are 100%. Some
peptides demonstrated binding to sera only at low dilu-
tion, while some maintained high binding ability even at
higher dilutions.
The following are the peptides (designated by NIH
AIDS Research & Reference Reagent Program in 2004)
to which patient LTNP sera demonstrated high binding
at dilution of 1:500: 2015 (TKAKRRVVQREKRAAI-
GALF ) (2), 2018 (SVTLTVQARL) (4), 2019 (QARLLLS
GIVQQQNNLLRAI) (5), 2020 (QQQNNLLRAIEAQQ
HMLQLT) (2), 2022 (VWGIKQLQARVLAVERYLKD)
(5), 2025 (GKLICTTTVPWNASWSNKSL ) (4), 2031
(LLELDKWASLWNWFDITNWL) (2), 2032 (DITNWL
WYIKI) (2), 2033 (5), 2038 (PEGIEEEGGERDRDT
SGRLV) (4), 2039 (RDRDTSGRLVHGFLAIIWVD) (2),
2040 (IWVDLRSLFLFSYH) (4), 2042 (HRDLLLIAARI
VELLGRRGW) (3), 2043 (IVELLGRRGWEVLKYWWNLL) (3), and 2046 (SLLNATAIAVAEGTDR) (2). The fol-
lowing peptides bound to LTNP sera at 1:2000 dilu-
tions: 2019 (4), 2025 (3), 2031 (3), 2032 (2), 2033 (3),
2038 (2), 2040 (3), and 2047 (AVAEGTDRVIEVLQRA
GRAI) (2).
When mapping the LTNP samples, containing anti-
bodies that bound with high affinity at low sera concen-
tration, we found that there was high protein homology
between them, representative of sequence conservation.
These results are presented in Figure 2 and Table 1.
LTNP sera mediated inhibition of MT-2 infection cells by
H9MN
Viral infection was inhibited both by cell-free LTNP sera
and sera from mice vaccinated with CL3 chimeric peptide
(containing an HIV neutralization epitope). The Figure 3A
demonstrates MT2 cell syncytia formation after infection
by cell-free H9MN virus. Sera from patient LTNP-2,
LTNP-3, LTNP-4, and patient 25 (LTNP-5), from which
the human monoclonal antibody CL3 was developed,
markedly inhibited syncytia formation (p < 0.05). In
Figure 3B (right graph), this shows inhibition of viral
infection using antisera generated from vaccinated mice
(AC peptide) binding to gp41 (Figure 3). All LTNP sera
samples inhibited syncytia formation in vitro (Figure 3A).
Due to the consequences, it gives credit to the idea that
there is motivating interest in studying LTNP sera and the
potential for finding additional neutralizing antibodies.
CL3 neutralized HIV-1 Clade B Clinical Isolate
The preparation of the monoclonal antibody has been
described by Dr. Cotropia et al. [34]. The peptide
GCSGKLICTTVPWNASWSNKSL, which has previ-
ously been determined to contain the HIV-neutralizing
epitope KLIC of the clone 3 (CL3) antibody, was used
to vaccinate mice in this experiment, and the antisera
Figure 2 Schematic of gp160 of HIV-1 MN and epitope mapping results. The results for epitope A-G are shown in the figure accompanying the
structure for the glycoprotein 160. The location and degree of overlap are shown in the figure also. The complementary information on this figure
is provided in Table 1.
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the CL3 antibody. Sera from patient 25 (LTNP-5), the
sera from which the human monoclonal antibody CL3
was developed, was used as a positive control. Sera
from mice vaccinated with the beta-amyloid peptide
served as a negative control. We generated several hu-
man monoclonal antibodies using sera from human pa-
tient 25 in our previous study, Cao et. al. (2004) [35],
and we found that CL3 binds to peptide 2025. This
antibody can successfully neutralize HIV-1 clade B clin-
ical isolate (Figure 4). The neutralization profile of CL3
is provided, along with results for two other established
HIV-neutralizing HuMabs (2F5 and 2G12). The con-
centration at which CL3 inhibits 50% of cellular infec-
tions by the 92 BR030 isolate was 2 μg/ml, while theTable 1 Summary of found epitopes from the study from LTN
Epitope Epitope sequence Location in gp160 Sequenc
A QARLLLSGIVQQQMNLLRAT Start: AA 541 100% ide
End: AA 560
B GCSGKLICTTTVPWNASWSNKSL Start: AA 598 95.7-100
End: AA 620
C LLELDKWASLWNWFDITNWLW Start: AA 661 100% ide
End: AA 681
D DITNWLWYIKI Start: AA 675 100% ide
End: AA 685
E WYIKIFIMIVGGLVGLRIVF Start: AA 681 90-100%
End: AA 700
F PEGIEEEGGERDRDTRGRLV Start: AA 731 85-100%
End: AA 750
G IWVDLRSLFLFSYH Start: AA 757 92.9-100
End: AA 770
CL3 GCSGKLICTT Start: AA 598 100% ide
End: AA 607
5 LTNP patients were assayed for 7 different epitopes and CL3 found to have a hig
HIV-1 MN gp160, and the sequence match between the samples is given in the tabsame value for 2F5 was 10 μg/ml. This indicates that
for this HIV-1 isolate, CL3 is more effective than 2 F5
at neutralizing the infection.CL3 and 2F5 are conserved epitopes, implying their
functional importance
Our results show that the CL3 and 2F5 epitopes are
highly conserved among different HIV-1 isolates, span-
ning clade A through U (Figure 5). The graph indicates
the percent epitope homology among different HIV iso-
lates across clades A through U for HuMab anti-HIV
neutralizing HuMab CL3 (epitope = 8 aa long) and 2F5
(epitope = 6 aa long). The graphs indicate that CL3 con-
sistently showed higher conservation than 2F5.P sera
e match
ntical (100 out of 100)
% identical (20 of 100, 100%; 75 of 100, 95.7%); core epitope KLIC is 100%
ntical (100 out of 100)
ntical (100 out of 100)
identical (3 of 100, 90%; 82 of 100, 95%; 15 of 100, 100%)
identical (8 of 100, 85%; 92 of 100, 100%)
% identical (2 of 100, 92.9%; 98 of 100, 100%)
ntical (100 out of 100)
h degree of matching. The epitope, epitope sequence, epitope location within
le.
Figure 3 Inhibition of viral infection by LTNP sera and vaccinated mice sera. Viral infection was measured after treatment with LTNP sera and sera
from mice vaccinated with a peptide containing an identified HIV neutralization epitope. A (left graph) demonstrated the MT2 cell syncytia formation
after infection by cell free H9MN virus. As shown in the figure, sera from patient LTNP-2, LTNP-3, LTNP-4, and LTNP-5 (patient 25) significantly inhibited
the syncytia formation (p < 0.05). B (right graph) shows antisera from the vaccinated mice (with the AC peptide) binding to gp41, and comparing this
binding titer to the positive control sera of patient 25 and the negative control sera of mice vaccinated with the beta amyloid peptide.
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from NHS
We conducted experiments regarding the levels of specific
markers of the immune system, mainly cytokines and
chemokines. Many cytokines were measured using theFigure 4 Neutralization Profiles. The neutralization profile from CL3 is provide
(2F5 and 2G12). A CL3 and 2F5 are compared against the negative control, a
against the positive control, 2G12. The concentration of CL3 that inhibits 50%
same value for 2F5 was 10 μg/ml. This indicates that, at least for this HIV-1 isoRayBioTM Human Cytokine Array Map V & 5.1
(Figure 6). The data from the cytokine and chemokine
array showed that chemokine CCL1 (I-309) and insu-
lin-like growth factor-1 (IGFBP1) showed significant
decreases, while TIMP metallopeptidase inhibitor 2d along with results for two other established HIV neutralizing HuMabs
control human monocolonal antibody. B CL3 and 2F5 are compared
of cellular infections by the 92 BR030 isolate was 2 μg/ml, while the
late, CL3 is more effective than 2F5 at neutralizing infection (p < 0.05).
Figure 5 Conservation of Epitopes across HIV-1 Clades A-U. As shown above, both the CL3 and 2F5 epitopes are conserved across all HIV-1
Clades A-U. CL3 appears to have a greater percent homology across clades than the already established 2F5.
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showed substantial increases (p < 0.05) (Figure 6, Table 2).
These results suggest that both the humoral and cellular
responses in the immune system of LTNP patients, mainly
the LNTP sera (e.g. antibodies), may play a more signifi-
cant role in preventing disease progression.Figure 6 RayBioTM Assay Human Cytokine Array. Select result of proteins th
manufacturers map of the array.Discussion
This report presents data pertaining to the use of bind-
ing and neutralization pattern assays used on the sera of
HIV-infected LTNP patients to guide the development
of HIV immunotherapy. Although a fair amount of work
has been carried out on this idea, there is currently noat showed a change in expression can be found in Table 2 and
Table 2 Protein changes in LTNPs samples versus normal
control
Protein Sample A Sample B Sample C Sample D PT25
I-309 (CCL1) −81.7% −94.3% −60.9% −49.9% −70.3%
IGFBP-1 −82.9% −72.4% −57.2% −55.9% −54.8%
TIMP-1 159.9% 44.3% 299.6% 226.2% 141.1%
NAP-2 95.6% 113.4% 142.7% 205.1% 190.1%
Percent change was calculated upon the quantification to protein array result
of each LTNPs sample using the following formula: (LTNPs-normal)/normal
X 100%.
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used clinically against HIV/AIDS.
In this report, we demonstrated that a LTNP serum
does, in fact, contain binding and neutralization infor-
mation that may contribute to the development of future
therapeutic antibody cocktail formation. The mapping
results, supported by the protein sequence homology
analysis, demonstrated that all identified epitopes are
highly conserved. More importantly, all potent neutraliz-
ing antibodies against gp41 (2F5, 4E10 and CL3) were
covered in our mapping result. This procedure may be
used on other components of the HIV virus to develop
potent neutralizing antibodies.
The high degree of conservation among epitopes for
HuMabs, such as CL3, may have success as immuno-
therapeutics against broadly divergent HIV-1 clades [36].
This is also backed by the cross-clade reactivity exhib-
ited by monoclonal antibodies to the CD4 binding do-
main, the C-terminus of gp120, and to regions on gp41
[17,22,37,38]. Unfortunately, the vaccine developed in
this study does not have an antibody as potent, in terms
of neutralizing capability, as CL3, which may be due to a
change in the epitope in the chimeric peptide. We are
currently working to further improve the function of the
chimeric vaccine, and plan to use this procedure to
study other portions of the HIV-1 clinical isolate.
As indicated, anti-HIV HuMAbs against conserved re-
gions of the gp41 envelope glycoprotein are candidates
for clinical use because of their ability to broadly
neutralize many clinical isolates. However, to date there
are only a few HuMAbs that possess neutralizing activ-
ity. Of note, 2F5 recognizes a relatively conserved region
in the ectodomain of gp41 near the transmembrane
region of the molecule [39]. Others are 4E10 and Z13,
which are specific for a region that is located immedi-
ately next to 2F5 epitope towards the carboxy terminal.
Interestingly, the “immunodominant domain” region,
which contains the epitope for CL3, has produced other
HuMAbs that have been shown not to have neutralizing
capabilities [40,41]. Viveros et al. reported that the CL3
epitope is linear and exists within the immunodominant
domain of gp41 but that it appears to be rarely immuno-
genic. This was based on an inability to producepolyclonal antibodies in rabbits against this epitope
using appropriate [32]. However, the generation and bio-
logical activity of the CL3 HuMAb indicate that, under
certain circumstances, this epitope is accessible, and
therefore not entirely immuno-silent. This suggests that
in some individuals, through mechanisms not com-
pletely understood, changes in accessibility occur during
the course of infection that result in an exposure of
these neutralization epitopes [36,42].
Protein array results from the cytokine assay identified
that I-309 and IGFBP-1 significantly reduced in LTNPS,
but TIMP-1 (tissue inhibitors of MMPs-1) and NAP-2
(neutrophil-activating protein-2) significantly increased
in those subjects. The roles of those cytokines are not
quite clear, but they are all related to active T cell func-
tion. It is important to mention, however, that I-309 can
inhibit X4 infection [43] and that IGFBP-1 is 100% posi-
tive in HIV infected subjects [44]. Activation of the
membrane-type-1-matrix-metalloproteinase and the in-
duction of the membrane-bound tissue inhibitor of
metalloproteinase-2 (TIMP-2) can increase HIV infec-
tion [45]. NAP-2 can enhance antiviral activity of INF
gamma [46]. Our result further suggests that the cellular
response here may also play a critical role in the preven-
tion of the progression of HIV to AIDS in diseased
subjects.
Additional research is needed to further characterize
the antibody library harbored in LTNP sera by using a
similar antibody-development procedure as used in this
study in finding the CL3 neutralizing antibody. In sum-
mary, the results we have reported demonstrate a poten-
tially reliable and practicable approach towards antibody
cocktail development, applicable for HIV prevention and
vaccine design. We may be able to obtain the solution to
deal with HIV/AIDS through the study of more LTNP
subjects.
Conclusions
Our results indicate that the use of LTNP samples may
be a useful for finding antibody cocktail candidates and
antiviral agents for the development of HIV/AIDS treat-
ments. The sera of the LTNP patients were found to be
able to bind to the same peptide as clone 3 (CL3), the
broad neutralizing HIV-neutralizing monoclonal anti-
body against gp41. This procedure may be replicated on
other portions of the HIV virus to develop equally po-
tent antibodies, like CL3, in the development of neutral-
izing antibodies or antibody compounds. When looking
further at the cytokine and chemokine changes in track-
ing the overall changes to the immune system, we found
that there were significant changes in a handful of cyto-
kine and cytokine markers. This suggests that both the
humoral and cellular immune responses play a role in
the prevention of HIV disease progression. We believe
Hao et al. BMC Immunology  (2015) 16:25 Page 9 of 10that CL3 may be clinically useful with regards to devel-
opment of antibodies and vaccines against HIV due to
its great potential for viral inhibition and its high bind-
ing affinity, and that further antibodies can be found
from LTNP patients with similar potency using the
methods presented here.
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